Furthermore, our findings can hopefully have important clinical implications in the fields of therapeutical in vivo NGF delivery in humans because not only constitute a molecular rationale for the existence of its limited therapeutic time window but also offer a prime useful presynaptic-based target with the intent of extending its neuroprotective action in AD intervention. This evidence concerns the gene NGF and Alzheimer disease.